Top

Published in:

01-06-2010

How to Mediate Cardioprotection in Ischemic Hearts—Accumulated Evidence of Basic Research Should Translate to Clinical Medicine

Author: Masafumi Kitakaze

Published in: Cardiovascular Drugs and Therapy | Issue 3/2010

Abstract

Ischemic heart failure is one of the leading causes of death in the western countries and it is a critical issue to overcome ischemic heart diseases for the human health care worldwide. There are several aspects of ischemic heart failure that we need to seriously consider for the conquest of cardiovascular death. First of all, we need to know either causes or pathophysiology of the onset of coronary artery disease, the ischemia/reperfusion injury and post-infarction cardiac remodeling. Secondly, we need to find the potential seeds for the molecular, pharmacological, biomedical or engineering treatment to prevent or attenuate ischemic heart diseases. Thirdly, we need to accelerate translational research and to create the network of clinical trials to grow the novel seeds to the fruitful big trees. Finally, we need to justify these strategies to overcome the ischemic heart diseases and to contribute the world welfare systems after we propose the novel therapy for the prevention and attenuation of ischemic heart diseases. The most strong and essential hypotheses to attenuate the cardiovascular injury in ischemic heart disease for last three decades are ischemic preconditioning/postconditioning. Many investigators have involved in the clarification of the characteristics of ischemic preconditioning/postconditioning and their cellular mechanisms, and the clinical applications of their basic results. Here, 8 potential basic and clinical researchers includeing us discuss these issues that they have devotedly studies for many years.

Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol. 2001;33:1897–918.CrossRefPubMed

Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2. Circulation. 2001;104:3158–67.CrossRefPubMed

Mubagwa K, Mullane K. Flameng Role of adenosine in the heart and circulation. Cardiovasc Res. 1996;32:797–813.PubMed

Kitakaze M, Minamino T, Node K, et al. Adenosine and cardioprotection in the diseased heart. Jpn Circ J. 1999;63:231–43.CrossRefPubMed

Chulz R, Cohen MV, Behrends M, Downey JM, Heusch G. Signal transduction of ischemic preconditioning. Cardiovasc Res. 2001;52:181–98.CrossRef

Kitakaze M. It is the time to ask what adenosine can do for cardioprotection in ischemic heart disease. Internal Medicine. 1999;38:305–6.CrossRefPubMed

Allen DG, Orchard CH. Myocardial contractile function during ischemia and hypoxia. Circ Res. 1987;60:153–68.PubMed

Mauser M, Hoffmeister HM, Nienaber C, Schaper W. Influence of ribose, adenosine, and “AICAR” on the rate of myocardial adenosine triphosphate synthesis during reperfusion after coronary artery occlusion in the dog. Circ Res. 1985;56:220–30.PubMed

Pike MM, Luo CS, Clark D, et al. NMR measurements of Na⁺ and cellular energy in the ischemic rat heart: role of Na⁺/H⁺ exchange. Am J Physiol. 1993;265:H2017–26.PubMed

10.

Marban E, Kitakaze M, Kusuoka H, Porterfield JP, Yue DT, Chacko VP. Intracellular free calcium concentration measured with ¹⁹F NMR spectroscopy in intact ferret hearts containing the Ca²⁺-indicator 5,5′-F2-BAPTA. Proceeding National Academy Science (U.S.A) 1987;84:6005-9.

11.

Sato H, Hori M, Kitakaze M, et al. Reperfusion after brief ischemia disrupts the microtuble structure in the canine hearts. Circ Res. 1993;72:361–75.PubMed

12.

Kitakaze M, Weisman HF, Marban E. Contractile dysfunction and ATP depletion following transient calcium overload in perfused ferret hearts. Circulation. 1988;77:685–95.PubMed

13.

Kitakaze M, Weisfeldt ML, Marban E. Acidosis during early reperfusion prevents myocardial stunning in perfused ferret hearts. J Clin Invest. 1988;82:920–7.CrossRefPubMed

14.

Kitakaze M, Takashima S, Minamino T, et al. Transient acidosis during early reperfusion following myocardial ischemia limits infarct size in the dogs. Am J Physiol. 1997;272:H2071–8.PubMed

15.

Taga R, Okabe E. Hydroxyl radical participation in the in vitro effects of gram-negative endotoxin on cardiac sarcolemmal Na, K-ATPase activity. Jpn J Pharmacol. 1991;55:339–49.CrossRefPubMed

16.

Kitakaze M, Hori M, Takashima S, et al. Superoxide dismutase enhances ischemia-induced reactive hyperemic flow and adenosine release in dogs: a role of 5′-nucleotidase activity. Circ Res. 1992;71:558–66.PubMed

17.

Gross GJ, Farber NE, Hardman HF, Warltier DC. Beneficial actions of superoxide dismutase and catalase in stunned myocardium of dogs. Am J Physiol. 1986;250:H372–7.PubMed

18.

Sekili S, McCay PB, Li XY, et al. Direct evidence that the hydroxyl radical plays a pathogenetic role in myocardial “stunning” in the conscious dog and demonstration that stunning can be markedly attenuated without subsequent adverse effects. Circ Res. 1993;73:705–23.PubMed

19.

Flaherty JT, Pitt B, Gruber JW, et al. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation. 1994;89:1982–91.PubMed

20.

Schömig A, Dart AM, Dietz R, Mayer E, Kübler W. Release of endogenous catecholamines in the ischemic myocardium of the rat. Part A: locally mediated release. Circ Res. 1984;55:689–701.PubMed

21.

Kitakaze M, Hori M, Tamai J, et al. α1-Adrenoceptor activity regulates release of adenosine from the ischemic myocardium in dogs. Circ Res. 1987;60:631–9.PubMed

22.

Kitakaze M, Hori M, Gotoh K, et al. Beneficial effects of α2-activity on ischemic myocardium during coronary hypoperfusion in dogs. Circ Res. 1989;65:1632–45.PubMed

23.

Huang AH, Feigl EO. Adrenergic coronary vasoconstriction helps maintain uniform transmural blood flow distribution during exercise. Circ Res. 1988;62:286–98.PubMed

24.

Kloner RA, Ganote CE, Jennings RB. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1987;54:1496–508.CrossRef

25.

Ito H, Maruyama A, Iwakura K, Takiuchi S, et al. Clinical implications of the ‘no reflow’ phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996;223–8.

26.

Hansen PR. Role of neutrophils in myocardial ischemia and reperfusion. Circulation. 1995;91:1872–85.PubMed

27.

Watanabe T, Suzuki N, Shimamoto N, Fujino M, Imada A. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res. 1991;69:370–7.PubMed

28.

Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest. 1994;94:1621–8.CrossRefPubMed

29.

Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124–36.PubMed

30.

Kuzuya T, Hoshida S, Yamashita N, et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res. 1993;72:1293–9.PubMed

31.

Marbar MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress associated with resistance to myocardial infarction. Circulation. 1993;83:13–25.

32.

Yang X, Cohen MV, Downey JM. Mechanism of cardioprotection by early ischemic preconditioning. Cardiovasc Drugs Ther 2010;24: this issue.

33.

Mura T, Tanno M. Mitochondria and GSK-3β in cardioprotection against ischemia/reperfusion injury. Cardiovasc Drugs Ther 2010;24: this issue.

34.

Hausenloy DJ, Yellon DM. The second window of preconditioning (SWOP). Where are we now? Cardiovasc Drugs Ther 2010;24: this issue.

35.

Hausenloy DJ, Yellon DM. Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res. 2008;79:377–86.CrossRefPubMed

36.

Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285:H579–88.PubMed

37.

Kin H, Zhao ZQ, Sun HY, et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res. 2004;62:74–85.CrossRefPubMed

38.

Sun HY, Wang NP, Kerendi F, et al. Hypoxic postconditioning reduces cardiomyocyte loss by inhibiting ROS generation and intracellular Ca2+ overload. Am J Physiol Heart Circ Physiol. 2005;288:H1900–8.CrossRefPubMed

39.

Zhao Z-Q. Postconditioning in reperfusion: a status report. Cardiovasc Drugs Ther 2010;24:this issue.

40.

Ishihara M, Sato H, Tateishi H, et al. Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and long-term prognosis. J Am Coll Cardiol. 1997;30:970–5.CrossRefPubMed

41.

Ross AM, Gibbons RJ, Stone GW, Kloner RA. Alexander RW; AMISTAD-II Investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005;45:1775–80.CrossRefPubMed

42.

Kitakaze M, Asakura M, Kim J, et al. On behalf of the J-WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007;370:1483–93.CrossRefPubMed

43.

Asakura M. Cardioprotection in the clinical setting—Lesson from J-WIND. Cardiovasc Drugs Ther 2010;24: this issue.

44.

Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473–81.CrossRefPubMed

45.

Ivanes F, Mewton N, Rioufol G, Piot C, Elbaz M, Revel D, et al. Cardioprotection in the clinical setting. Cardiovasc Drugs Ther 2010;24: this issue.

Title: How to Mediate Cardioprotection in Ischemic Hearts—Accumulated Evidence of Basic Research Should Translate to Clinical Medicine
Author: Masafumi Kitakaze
Publication date: 01-06-2010
Publisher: Springer US
Published in: Cardiovascular Drugs and Therapy / Issue 3/2010
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-010-6248-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

How to Mediate Cardioprotection in Ischemic Hearts—Accumulated Evidence of Basic Research Should Translate to Clinical Medicine

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

Rapamycin can Inhibit the Development of Chlamydia pneumoniae, which Might Partly Contribute to the Prevention of In-stent Restenosis

Postconditioning in Reperfusion Injury: A Status Report

The Second Window of Preconditioning (SWOP) Where Are We Now?

Role of Dual Antiplatelet Therapy in Symptomatic Patients with Established Vascular Disease: Putting the CHARISMA Trial into Therapeutic Perspective

Cardioprotection in the Clinical Setting

Cardioprotection in the Clinical Setting-Lessons from J-WIND Studies

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page